OmegaGenesis Announces Angiogenesis Application Collaboration
News Dec 16, 2008
OmegaGenesis announced that they have entered into a collaboration with Mayo Clinic for the discovery and validation of nano-materials used for Angiogenesis applications.
Angiogenesis plays an important role in a wide variety of medical applications ranging from tissue reactivation and healing of common wounds to controlling the growth and spread of cancer and malignancies.
In cancer and malignancies, new blood vessels feed the cancer cells with oxygen and nutrients, allowing these cells to grow, invade nearby tissue, spread to other parts of the body, and form new colonies of cancer cells.
At Mayo Clinic, researchers have produced one of the rare earth materials in nano size and established non-toxicity of the material for human applications.
Additionally they have shown the material induces endothelial cell growth and produces new blood vessels. Considering the current limitation of therapy to create new functional blood vessels in ischemic diseases, this finding has significant potential for clinical application.
OmegaGenesis is developing applications based on these unique characteristics of nano materials for proactive maintenance of the human body. "Our goal is to supplement natural human body management and re-enable where some natural processes have stopped or diminished. These diminished capabilities lead to dysfunction of human body. Our approach provides for early and pre-disease intervention in most cases," said Mr. Raza, CEO of OmegaGenesis.
"Our collaboration with Mayo Clinic is an example of a strategically important long-term relationship. As a result of this research and product development collaboration, fundamental research conducted by Mayo Clinic is used by OmegaGenesis in the product development process and marketplace applications," said Oostur Raza.
It is this collaborative process in research and product development together with venture funding that allows OmegaGenesis to advance the treatment of primary diseases potentially affecting hundreds of millions globally.
OmegaGenesis through its collaboration with Mayo Clinic has retained exclusive license to further test Angiogenesis characteristics of these nano rods and develop products. The agreement includes existing intellectual property and a commitment to ongoing collaborative research projects in early-development stages at Mayo Clinic.
In addition to licensing technology and patents to OmegaGenesis, Mayo Clinic and OmegaGenesis scientists will cooperate in conducting lab tests.
University of Wisconsin–Madison Professor of Chemistry Shannon Stahl has received the Steenbock Professorship in Chemical Sciences. In addition to advancing the fundamental science in this area, Stahl has been involved in numerous industrial collaborations that have led to practical applications, including target applications relevant to pharmaceutical synthesis.READ MORE